Noninvasive biomarkers in NAFLD and NASH — current progress and future promise

Autores
Wong, Vincent Wai-Sun; Adams, Leon A.; de Lédinghen, Victor; Wong, Grace Lai-Hung; Sookoian, Silvia Cristina
Año de publicación
2018
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Nonalcoholic fatty liver disease (NAFLD) affects 25% of the global adult population and is the most common chronic liver disease worldwide. Nonalcoholic steatohepatitis (NASH) is the active form of NAFLD, with hepatic necroinflammation and faster fibrosis progression. With an increasing number of patients developing NASH-related end-stage liver disease and pharmacological treatments on the horizon, there is a pressing need to develop NAFLD and NASH biomarkers for prognostication, selection of patients for treatment and monitoring. This requirement is particularly true as liver biopsy utility is limited by its invasive nature, poor patient acceptability and sampling variability. This article reviews current and potential biomarkers for different features of NAFLD, namely, steatosis, necroinflammation and fibrosis. For each biomarker, we evaluate its accuracy, reproducibility, responsiveness, feasibility and limitations. We cover biochemical, imaging and genetic biomarkers and discuss biomarker discovery in the omics era.
Fil: Wong, Vincent Wai-Sun. Chinese University Of Hong Kong; Hong Kong
Fil: Adams, Leon A.. University of Western Australia; Australia
Fil: de Lédinghen, Victor. Universite de Bordeaux; Francia
Fil: Wong, Grace Lai-Hung. Chinese University Of Hong Kong; Hong Kong
Fil: Sookoian, Silvia Cristina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Médicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; Argentina
Materia
NASH
NAFLD
BIOMARKERS
OMICS
Nivel de accesibilidad
acceso abierto
Condiciones de uso
Atribución-NoComercial-CompartirIgual 2.5 Argentina (CC BY-NC-SA 2.5 AR)
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/86757
Acceder
id CONICETDig_eaccc187c6be2590d8c693d513bb9378
oai_identifier_str oai:ri.conicet.gov.ar:11336/86757
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Noninvasive biomarkers in NAFLD and NASH — current progress and future promiseWong, Vincent Wai-SunAdams, Leon A.de Lédinghen, VictorWong, Grace Lai-HungSookoian, Silvia CristinaNASHNAFLDBIOMARKERSOMICShttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Nonalcoholic fatty liver disease (NAFLD) affects 25% of the global adult population and is the most common chronic liver disease worldwide. Nonalcoholic steatohepatitis (NASH) is the active form of NAFLD, with hepatic necroinflammation and faster fibrosis progression. With an increasing number of patients developing NASH-related end-stage liver disease and pharmacological treatments on the horizon, there is a pressing need to develop NAFLD and NASH biomarkers for prognostication, selection of patients for treatment and monitoring. This requirement is particularly true as liver biopsy utility is limited by its invasive nature, poor patient acceptability and sampling variability. This article reviews current and potential biomarkers for different features of NAFLD, namely, steatosis, necroinflammation and fibrosis. For each biomarker, we evaluate its accuracy, reproducibility, responsiveness, feasibility and limitations. We cover biochemical, imaging and genetic biomarkers and discuss biomarker discovery in the omics era.Fil: Wong, Vincent Wai-Sun. Chinese University Of Hong Kong; Hong KongFil: Adams, Leon A.. University of Western Australia; AustraliaFil: de Lédinghen, Victor. Universite de Bordeaux; FranciaFil: Wong, Grace Lai-Hung. Chinese University Of Hong Kong; Hong KongFil: Sookoian, Silvia Cristina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Médicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; ArgentinaNature Publishing Group2018-08info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/86757Wong, Vincent Wai-Sun; Adams, Leon A.; de Lédinghen, Victor; Wong, Grace Lai-Hung; Sookoian, Silvia Cristina; Noninvasive biomarkers in NAFLD and NASH — current progress and future promise; Nature Publishing Group; Nature Reviews Gastroenterology & Hepatology; 15; 8; 8-2018; 461-4781759-5045CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/http://www.nature.com/articles/s41575-018-0014-9info:eu-repo/semantics/altIdentifier/doi/10.1038/s41575-018-0014-9info:eu-repo/semantics/openAccessAtribución-NoComercial-CompartirIgual 2.5 Argentina (CC BY-NC-SA 2.5 AR)https://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:33:45Zoai:ri.conicet.gov.ar:11336/86757instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:33:45.615CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Noninvasive biomarkers in NAFLD and NASH — current progress and future promise
title Noninvasive biomarkers in NAFLD and NASH — current progress and future promise
spellingShingle Noninvasive biomarkers in NAFLD and NASH — current progress and future promise
Wong, Vincent Wai-Sun
NASH
NAFLD
BIOMARKERS
OMICS
title_short Noninvasive biomarkers in NAFLD and NASH — current progress and future promise
title_full Noninvasive biomarkers in NAFLD and NASH — current progress and future promise
title_fullStr Noninvasive biomarkers in NAFLD and NASH — current progress and future promise
title_full_unstemmed Noninvasive biomarkers in NAFLD and NASH — current progress and future promise
title_sort Noninvasive biomarkers in NAFLD and NASH — current progress and future promise
dc.creator.none.fl_str_mv Wong, Vincent Wai-Sun
Adams, Leon A.
de Lédinghen, Victor
Wong, Grace Lai-Hung
Sookoian, Silvia Cristina
author Wong, Vincent Wai-Sun
author_facet Wong, Vincent Wai-Sun
Adams, Leon A.
de Lédinghen, Victor
Wong, Grace Lai-Hung
Sookoian, Silvia Cristina
author_role author
author2 Adams, Leon A.
de Lédinghen, Victor
Wong, Grace Lai-Hung
Sookoian, Silvia Cristina
author2_role author
author
author
author
dc.subject.none.fl_str_mv NASH
NAFLD
BIOMARKERS
OMICS
topic NASH
NAFLD
BIOMARKERS
OMICS
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Nonalcoholic fatty liver disease (NAFLD) affects 25% of the global adult population and is the most common chronic liver disease worldwide. Nonalcoholic steatohepatitis (NASH) is the active form of NAFLD, with hepatic necroinflammation and faster fibrosis progression. With an increasing number of patients developing NASH-related end-stage liver disease and pharmacological treatments on the horizon, there is a pressing need to develop NAFLD and NASH biomarkers for prognostication, selection of patients for treatment and monitoring. This requirement is particularly true as liver biopsy utility is limited by its invasive nature, poor patient acceptability and sampling variability. This article reviews current and potential biomarkers for different features of NAFLD, namely, steatosis, necroinflammation and fibrosis. For each biomarker, we evaluate its accuracy, reproducibility, responsiveness, feasibility and limitations. We cover biochemical, imaging and genetic biomarkers and discuss biomarker discovery in the omics era.
Fil: Wong, Vincent Wai-Sun. Chinese University Of Hong Kong; Hong Kong
Fil: Adams, Leon A.. University of Western Australia; Australia
Fil: de Lédinghen, Victor. Universite de Bordeaux; Francia
Fil: Wong, Grace Lai-Hung. Chinese University Of Hong Kong; Hong Kong
Fil: Sookoian, Silvia Cristina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Médicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; Argentina
description Nonalcoholic fatty liver disease (NAFLD) affects 25% of the global adult population and is the most common chronic liver disease worldwide. Nonalcoholic steatohepatitis (NASH) is the active form of NAFLD, with hepatic necroinflammation and faster fibrosis progression. With an increasing number of patients developing NASH-related end-stage liver disease and pharmacological treatments on the horizon, there is a pressing need to develop NAFLD and NASH biomarkers for prognostication, selection of patients for treatment and monitoring. This requirement is particularly true as liver biopsy utility is limited by its invasive nature, poor patient acceptability and sampling variability. This article reviews current and potential biomarkers for different features of NAFLD, namely, steatosis, necroinflammation and fibrosis. For each biomarker, we evaluate its accuracy, reproducibility, responsiveness, feasibility and limitations. We cover biochemical, imaging and genetic biomarkers and discuss biomarker discovery in the omics era.
publishDate 2018
dc.date.none.fl_str_mv 2018-08
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/86757
Wong, Vincent Wai-Sun; Adams, Leon A.; de Lédinghen, Victor; Wong, Grace Lai-Hung; Sookoian, Silvia Cristina; Noninvasive biomarkers in NAFLD and NASH — current progress and future promise; Nature Publishing Group; Nature Reviews Gastroenterology & Hepatology; 15; 8; 8-2018; 461-478
1759-5045
CONICET Digital
CONICET
url http://hdl.handle.net/11336/86757
identifier_str_mv Wong, Vincent Wai-Sun; Adams, Leon A.; de Lédinghen, Victor; Wong, Grace Lai-Hung; Sookoian, Silvia Cristina; Noninvasive biomarkers in NAFLD and NASH — current progress and future promise; Nature Publishing Group; Nature Reviews Gastroenterology & Hepatology; 15; 8; 8-2018; 461-478
1759-5045
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://www.nature.com/articles/s41575-018-0014-9
info:eu-repo/semantics/altIdentifier/doi/10.1038/s41575-018-0014-9
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
Atribución-NoComercial-CompartirIgual 2.5 Argentina (CC BY-NC-SA 2.5 AR)
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv Atribución-NoComercial-CompartirIgual 2.5 Argentina (CC BY-NC-SA 2.5 AR)
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Nature Publishing Group
publisher.none.fl_str_mv Nature Publishing Group
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613039558492160
score 13.069144

Publicaciones similares